By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment bank Canaccord Genuity has cut its price target on Gen-Probe's stock to $75 from $88, saying that there appears to be no competitive bids to acquire the molecular diagnostics firm.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: the Human Silencing Hub protein complex, and more.
Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.
The Kansas City Star examines issues surrounding newborn genome sequencing.
Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.